TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback